portalcascais.pt Traffic Analytics & Website Stats
Encontre todos os artigos mais recentes e veja programas de TV, reportagens e podcasts relacionados com Portugal em portalcascais.pt
portalcascais.pt is a domain having .pt extension. portalcascais.pt is a news and media website. portalcascais.pt gets 11,694 traffic per month, the site is estimated to be worth $6,958.00. Over the last three months, portalcascais.pt's global ranking has decreased from 1,922,056 to 3,298,192. portalcascais.pt's traffic has increased by 52.79% compared to last month, which is already a sign. Which countries sent the most traffic to portalcascais.pt lately? Last month Portugal was the top country sending traffic to portalcascais.pt. portalcascais.pt's audience is 55.95% male and 44.05% female. The largest age group of visitors are 25 - 34 year olds.
Updated 2 years ago
Web Analysis
- Traffic Report
-
Monthly Unique Visitors:
9,664
-
Monthly Pageviews:
11,694
- Estimated Valuation
-
Income Per Day:
$ 14
-
Estimated Worth:
$ 6,958
- Geography & Country Targeting
-
Countries Total Count:
6
-
Hot Country & Region:
Portugal
- Search keywords & Backlinks
-
Keywords Total Count:
41
-
Backlinks Sites:
0
- Global Ranks
-
Global Rank:
3,298,192
-
Country Rank:
2,170
- Global Rank Change
-
Global Rank Change:
+558,591
-
Country Rank Change:
+7,486
- Web Information
- HTTP Information
- Whois Information
Web Server Information
-
Hosted IP Address:
178.128.174.83
-
Hosted Country:
GB
-
Location Latitude:
51.383758544922
-
Location Longitude:
0.040839999914169
Page Title of portalcascais.pt
portalcascais.pt
Meta Description of portalcascais.pt
Encontre todos os artigos mais recentes e veja programas de TV, reportagens e podcasts relacionados com Portugal em portalcascais.pt
Meta Tags of portalcascais.pt
Website Inpage Analysis
-
H1 Headings:
1
-
H2 Headings:
17
-
H3 Headings:
6
-
H4 Headings:
0
-
H5 Headings:
0
-
H6 Headings:
0
-
Total IFRAMEs:
0
-
Total Images:
2
-
Total Forms:
1
-
Total Scripts:
7
-
Google Adsense:
No Data
-
Google Analytics:
No Data
HTTP Header Analysis
HTTP/1.1 200 OK
last-modified: Sun, 13 Nov 2022 11:02:49 GMT
content-type: text/html; charset=UTF-8
content-encoding: gzip
vary: Accept-Encoding
content-length: 10910
date: Sun, 13 Nov 2022 11:21:55 GMT
server: LiteSpeed
alt-svc: h3=":443"; ma=2592000, h3-29=":443"; ma=2592000, h3-Q050=":443"; ma=2592000, h3-Q046=":443"; ma=2592000, h3-Q043=":443"; ma=2592000, quic=":443"; ma=2592000; v="43,46"
connection: close
last-modified: Sun, 13 Nov 2022 11:02:49 GMT
content-type: text/html; charset=UTF-8
content-encoding: gzip
vary: Accept-Encoding
content-length: 10910
date: Sun, 13 Nov 2022 11:21:55 GMT
server: LiteSpeed
alt-svc: h3=":443"; ma=2592000, h3-29=":443"; ma=2592000, h3-Q050=":443"; ma=2592000, h3-Q046=":443"; ma=2592000, h3-Q043=":443"; ma=2592000, quic=":443"; ma=2592000; v="43,46"
connection: close
Full WHOIS Lookup
Similarly Ranked Websites
-
vupulse makes digital marketing and advertising more effective for marketers, more profitable for brands, and better experiences for consumers.
vupulse.com 414,897
-
webtic.it
webtic.it 134,046
-
Nikos Pekiaridis/NurPhoto via Getty Images(NEW YORK) -- Pfizer and BioNTech have launched a clinical trial on a vaccine targeting both COVID-19 and influenza, the companies announced Thursday. The phase 1 trial is being done in the United States with 180 participants between the ages of 18 and 64, with the first participant dosed this week, the companies said. The follow-up period for each participant will be six months. "By combining both indications in one vaccine approach, we aim to provide individuals with an efficient way to receive immunization against two severe respiratory diseases with evolving viruses that require vaccine adaptation," Dr. Ugur Sahin, CEO and co-founder of BioNTech, said in a statement. The combination vaccine is based on the currently available bivalent COVID-19 booster and a quadrivalent mRNA flu vaccine, which is designed to protect against four different flu viruses. The phase 1 trial will test for safety, immune response and optimal dose level of the combination vaccine, before moving on to larger trials. The data will also provide insight into the potential of mRNA vaccines to address more than one pathogen, Sahin said. Annaliesa Anderson, senior vice president and chief scientific officer of vaccine research and development for Pfizer, called this an "exciting step in our ongoing journey with BioNTech as we collectively look to transform the prevention of infectious diseases around the world." "Even with existing seasonal influenza vaccines, the burden of this virus is severe across the world causing thousands of deaths and hospitalizations every year," she said in a statement. Studies indicate COVID-19 vaccine efficacy fades over time, though it's not clear if every American will need an annual COVID-19 booster. As scientists continue to assess the need, several companies are at work on creating a single injection each fall that protects against both seasonal flu and COVID-19. In addition to Pfizer, pharmaceutical companies Moderna and Novavax have announced plans to work on a combo shot. Moderna said it anticipates starting clinical trials on a single-dose vaccine that combines a booster against COVID-19 and a booster against flu by the end of the year, with hopes of the vaccine being available for the 2023 season. "We believe this is a very large opportunity that is ahead of us, if we could bring to market a high efficacy pan-respiratory annual booster," Moderna COE Stéphane Bancel said during the Sept. 9 investor meeting. Last year, Novavax enrolled people in a Phase 1/2 study to evaluate the safety, tolerability and immune response of a combination vaccine using the company's seasonal influenza and COVID-19 vaccines. A phase 2 confirmation trial is expected to begin later this year, the company said in October. Copyright © 2022, ABC Audio. All rights reserved.
mycentraloregon.com 1,173,413
-
village cines ahora es cinépolis. este es tu cine. ¡entrá! los últimos estrenos. más que ver una película. una salida placentera. excelente servicio.
tickets.cinepolis.com.ar 74,231
-
buy.palacecinemas.com.au
buy.palacecinemas.com.au 83,562
-
experience.cineworld.co.uk
experience.cineworld.co.uk 9,954
-
Wij vertonen een breed programma aan prachtige films in hartje Dordrecht. Kom snel bij ons langs en ontdek een wereld aan cultuur en cinema.
themoviesdordrecht.nl 952,988
-
muvi Cinemas is the first home-grown cinema brand to the Kingdom of Saudi Arabia. Established in 2019 with headquarters in Riyadh, it is owned and operated by muvi Cinemas Co. muvi has an aggressive expansion plan over the next 24 months and will operate over 250 screens across the region offering customers a vast range of unique experiences. On 10 August 2019, muvi Cinemas opened its first location in Mall Of Arabia, Jeddah.
purchase.muvicinemas.com 33,469
-
Offizielle Webseite von Paramount Pictures Germany. Hier findest du aktuelle und zukünftige Informationen über Filme und Trailer!
paramount.de 1,691,703
-
Sports collecting news and features. Original content centered on modern and vintage sports cards and collectibles. Links to items for sale.
sportscollectorsdaily.com 298,959